Technology Licensing Opportunity

Non-Confidential Summary

VACCINE AGAINST INCLUSION BODY HEPATITIS
ROI# 09-009

Opportunity:

Researchers at the University of Saskatchewan have produced a novel vaccine against inclusion body hepatitis in broiler chickens. No live vaccine against a wide range of adenoviral strains is currently available.

Background:

Inclusion body hepatitis is the most prevalent infectious disease affecting the poultry industry in Canada *(Gomis S. et al, 2006)* and is an emerging problem worldwide. In Canada, the annual direct costs associated with this disease are estimated at over $10 million.

Inclusion body hepatitis is caused by fowl adenovirus (FAdV) and lasts 7-14 days with a mortality rate of 5-30%. FAdV infection affects chickens from 10 days to 6 weeks old.

Vaccine benefits:

- Superior protection of parents and progeny against a range of adenoviral strains, including homologous and heterologous strains,
- Composed of FAdV-2, FAdV-7, FAdV-8a/8b or FAdV-11 serotype strains
- Efficient and easy delivery routes, including “water supplementation”

Industry Liaison Office
121 Research Drive, Suite 501
Saskatoon, SK, S7N 1K2
Tel: (306) 966-1465 | Fax: (306) 966-7806

Technology Licensing Opportunity

Non-Confidential Summary

LIVE VACCINE AGAINST INCLUSION BODY HEPATITIS
ROI# 09-009

Researcher profile:

Dr. Susantha Gomis
Professor, Dept. of Veterinary Pathology, WCVM

Research interests: basic and applied aspects of pathogenesis and control of viral and bacterial diseases in poultry and mammalian species.

Patent Status:

US patent application no. 12/969,444
CA patent application no. 2,725,435

Publications:

1. Gomis S, Goodhope R, Ojkic D, and Wilson P. Inclusion Body Hepatitis as a Primary Disease in Broilers in Saskatchewan. Canada Avian Diseases, 50(4):550-555 (2006).
2. Ojkic D, Martin E, Swinton J, Vaillancourt JP, Boulianne M, and Gomis S. Genotyping of Canadian isolates of fowl adenoviruses. Avian Pathol. 37(1): 95-100 (2008b).

Development Stage:

Product is ready for licensing to a commercial partner.

For more information, please contact:

Johnny Xavier, PhD, MBA
Tel. (306) 966-7829
johnny.xavier@usask.ca

Oksana Akhova, PhD, MBA
Tel. (306) 966 5496
oksana.akhova@usask.ca